The three award types are: The Cancer Research UK Lifetime Accomplishment in Cancer Research Prize; The Cancer Study UK Prize for Translational Malignancy Research and the Malignancy Research UK Upcoming Leaders Prize. A global panel of world-renowned cancer professionals will consider the nominations and the prizes will become awarded as of this year’s National Tumor Research Institute Cancers Conference in November. The Life time Achievement Prize recognises an individual who has demonstrated an eternity dedication to the fight cancer making exceptional advances in the field, who has had a substantial and sustained role in furthering our knowledge of cancer, or a major effect on the lives of people with cancer.4 million for the 90 days ended June 30, 2014.7 million.5 million, primarily because of additional costs of operating mainly because a listed company publicly.2 million for the three months ended June 30, 2014.20 per talk about , for the 90 days ended June 30, 2014. The weighted average amount of shares utilized to calculate diluted and simple net loss per share was 23,970,242 and 10,801,948, respectively, for the three months ended June 30, 2015 and 2014. As of 30 June, 2015, there were 24,196,826 normal shares and 2,638,778 warrants exceptional. Each warrant entitles a warrant holder to subscribe for one ordinary share.05.9 million for the six months ended June 30, 2014.2 million in revenue from our collaboration with United Therapeutics due to the collaboration period ending at June 30, 2014.1 million compared to the same period in 2014.